Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Published:2021-05 Issue:5 Volume:22 Page:678-689
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Matasar Matthew J,Capra Marcelo,Özcan Muhit,Lv Fangfang,Li Wei,Yañez Eduardo,Sapunarova Katya,Lin Tongyu,Jin Jie,Jurczak Wojciech,Hamed Aryan,Wang Ming-Chung,Baker Ross,Bondarenko Igor,Zhang Qingyuan,Feng Jifeng,Geissler Klaus,Lazaroiu Mihaela,Saydam Guray,Szomor Árpád,Bouabdallah Krimo,Galiulin Rinat,Uchida Toshiki,Soler Lidia Mongay,Cao Anjun,Hiemeyer Florian,Mehra Aruna,Childs Barrett H,Shi Yuankai,Zinzani Pier Luigi

Funder

Bayer AG

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Global patterns and trends in the incidence of non-Hodgkin lymphoma;Miranda-Filho;Cancer Causes Control,2019

2. Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature;Juárez-Salcedo;Drugs Context,2020

3. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience;Salles;Adv Ther,2017

4. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment;Davis;J Clin Oncol,2000

5. Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients;Albarmawi;Future Oncol,2020

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of Staphylococcus aureus protein a (SpA) on the expression of inflammatory cytokines in autoimmune patients and their probable immune response modulation mechanisms;Cytokine;2024-11

2. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11

3. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma;Blood Advances;2024-09-24

4. New Agents in Marginal Zone Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10